Guardant Health director proposes $31K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Guardant Health, Inc. director Alex M Azar II reported that 207 common shares may be sold, with an aggregate market value of $30,959 and an approximate sale date of November 16, 2026. The notice lists Charles Schwab & Co., Inc. as broker. The shares were acquired through a restricted-stock lapse on November 12, 2026, as equity compensation. The notice also lists prior sales of 826 shares on September 16, 2026, for gross proceeds of $144,550, and 69 shares on October 14, 2026, for gross proceeds of $11,032.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Restricted Stock Lapse financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What date is listed for Alex M Azar II's GH Rule 10b5-1 plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.